Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.
J. Clin. Oncol., Dec (2012)
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.
Nucl Med Commun., Dec;33(12):1225-31 (2012)
Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.
Best Pract Res Clin Haematol., Jun;25(2):165-74 (2012)
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
Blood., Jun;119(26):6379-81 (2012)
Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.
Clin Lymphoma Myeloma Leuk., Aug;12(4):280-3 (2012)
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
Blood., Jul;120(3):560-8 (2012)
Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.
Korean J Hematol., Mar;47(1):8-16 (2012)
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
J. Clin. Oncol., Jun;30(18):2183-9 (2012)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Blood., Apr;119(17):3940-50 (2012)
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.
J Clin Apher., 27(2):81-7 (2012)
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Clin. Cancer Res., Dec;17(23):7373-82 (2011)
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
J. Clin. Oncol., Aug;29(22):3023-9 (2011)
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Blood., Jul;118(3):703-11 (2011)
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Oct;17(10):1537-45 (2011)
â¹â°Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Blood., Jul;118(4):1132-9 (2011)
In-vivo purging of the circulating clonal T-cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation.
Br. J. Haematol., Aug;154(3):415-8 (2011)
Blood-based detection of radiation exposure in humans based on novel phospho-Smc1 ELISA.
Radiat. Res., Mar;175(3):266-81 (2011)
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
J. Clin. Oncol., Mar;29(9):1190-7 (2011)
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Blood., Nov;116(20):4231-9 (2010)
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Leuk. Lymphoma., Aug;51(8):1523-9 (2010)